Largest Prospective Study to Date Further Supports Performance of DecisionDx-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result - Seite 2

The presented abstract described above can be viewed online in the ARVO Meeting Planner.

About DecisionDx-UM

DecisionDx-UM is Castle Biosciences’ 15-gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict individual risk of metastasis in patients with uveal melanoma (UM). DecisionDx-UM is the standard of care in the management of newly diagnosed UM in the majority of ocular oncology practices in the United States. Since 2009, the American Joint Committee on Cancer (AJCC; v7 and v8) Staging Manual for UM has specifically identified the GEP test as a prognostic factor that is recommended for collection as a part of clinical care. Further, the National Comprehensive Cancer Network (NCCN) guidelines for UM include the DecisionDx-UM test result as a prognostic method for determining risk of metastasis and recommended differential surveillance regimens based on a Class 1A, 1B and 2 result. DecisionDx-UM is currently the only prognostic test for UM that has been validated in prospective, multi-center studies, and it has been shown to be a superior predictor of metastasis compared to other prognostic factors, such as chromosome 3 status, mutational status, AJCC stage and cell type. It is estimated that nearly 8 in 10 patients diagnosed with UM in the United States receive the DecisionDx-UM test as part of their diagnostic workup. More information about the test and disease can be found here.

About DecisionDx-PRAME

Castle Biosciences offers testing with DecisionDx-PRAME as an optional add-on to the DecisionDx-UM test. PRAME (preferentially expressed antigen in melanoma) is an antigen gene that is not expressed at appreciable levels in normal adult tissues, but its expression can become aberrantly increased in some types of cancer, including melanoma. Once expressed, the PRAME protein can be processed and presented on the surface of cells, thereby serving as a potential target for therapeutic intervention. PRAME-directed therapies are being explored in multiple cancer types, including uveal melanoma. More information about DecisionDx-PRAME can be found here.

About the Collaborative Ocular Oncology Group

The Collaborative Ocular Oncology Group (COOG) is the largest collaborative working group in North America comprised of ocular and medical oncologists specialized in the treatment of patients with intraocular cancers, currently focusing on UM. The group is dedicated to a collaborative, evidence-based approach to advancing the care of patients with UM and other eye cancers through precision diagnostic, prognostic and therapeutic breakthroughs. Comprised of more than 25 leading academic and private ocular oncology centers of excellence, the COOG has been continually funded by the National Cancer Institute for over a decade. The COOG has conducted two large multi-center prospective studies of prognostic biomarkers in UM, the first and only such studies ever conducted in this cancer to date, and is planning a major expansion into adjuvant and metastatic clinic trials in patients with UM. More information about the COOG can be found here.